Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARDX Ardelyx	$4.42 +0.2%	$3.93	$3.21 ▼ $7.18	$1.06B	0.6	4.40 million shs	3.87 million shs
AUPH Aurinia Pharmaceuticals	$8.62 -0.1%	$8.16	$5.20 ▼ $10.67	$1.17B	1.16	1.41 million shs	1.32 million shs
AURA Aura Biosciences	$6.77 +0.9%	$6.26	$4.35 ▼ $12.38	$337.30M	0.45	210,198 shs	141,314 shs
GPCR Structure Therapeutics	$18.13 -5.8%	$21.73	$13.22 ▼ $45.37	$1.10B	-1.87	816,290 shs	1.00 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARDX Ardelyx	+0.23%	-4.12%	+24.16%	-8.11%	-19.78%
AUPH Aurinia Pharmaceuticals	-0.12%	-4.65%	+10.94%	+9.25%	+55.04%
AURA Aura Biosciences	+0.89%	+0.30%	+12.09%	+18.56%	-21.91%
GPCR Structure Therapeutics	-5.82%	-7.36%	-16.57%	-21.31%	-51.58%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARDX Ardelyx	3.989 of 5 stars	3.5	1.0	4.4	2.0	2.5	0.6
AUPH Aurinia Pharmaceuticals	3.2517 of 5 stars	3.5	2.0	0.0	3.6	0.8	1.9
AURA Aura Biosciences	2.6879 of 5 stars	3.6	1.0	0.0	3.4	3.3	0.0
GPCR Structure Therapeutics	2.191 of 5 stars	3.5	3.0	0.0	0.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARDX Ardelyx	3.00	Buy	$10.89	146.35% Upside
AUPH Aurinia Pharmaceuticals	3.00	Buy	$11.50	33.41% Upside
AURA Aura Biosciences	3.25	Buy	$22.00	224.96% Upside
GPCR Structure Therapeutics	3.00	Buy	$76.17	320.11% Upside

Current Analyst Ratings Breakdown

Latest AURA, ARDX, GPCR, and AUPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/23/2025	GPCR Structure Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$65.00
6/23/2025	GPCR Structure Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$89.00
6/18/2025	ARDX Ardelyx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00
5/28/2025	AURA Aura Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$22.00
5/23/2025	AURA Aura Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$19.00
5/12/2025	GPCR Structure Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $75.00
5/2/2025	ARDX Ardelyx	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $10.00
5/2/2025	ARDX Ardelyx	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Outperform	$11.00
5/2/2025	GPCR Structure Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00
4/22/2025	GPCR Structure Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00

(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARDX Ardelyx	$361.71M	2.92	N/A	N/A	$0.73 per share	6.05
AUPH Aurinia Pharmaceuticals	$235.13M	4.95	$0.31 per share	27.98	$2.68 per share	3.22
AURA Aura Biosciences	N/A	N/A	N/A	N/A	$3.04 per share	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	$15.10 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARDX Ardelyx	-$39.14M	-$0.22	N/A	14.26	N/A	-14.86%	-34.45%	-13.81%	7/30/2025 (Estimated)
AUPH Aurinia Pharmaceuticals	$5.75M	$0.28	30.79	15.39	N/A	16.11%	14.27%	9.93%	7/30/2025 (Estimated)
AURA Aura Biosciences	-$86.92M	-$1.90	N/A	N/A	N/A	N/A	-58.63%	-49.74%	8/14/2025 (Estimated)
GPCR Structure Therapeutics	-$122.53M	-$0.87	N/A	N/A	N/A	N/A	-16.35%	-15.71%	8/6/2025 (Estimated)

Latest AURA, ARDX, GPCR, and AUPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	AURA Aura Biosciences	-$0.47	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	GPCR Structure Therapeutics	-$0.28	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	ARDX Ardelyx	-$0.12	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	AUPH Aurinia Pharmaceuticals	$0.18	N/A	N/A	N/A	$64.27 million	N/A
5/15/2025	Q1 2025	AURA Aura Biosciences	-$0.47	-$0.55	-$0.08	-$0.55	N/A	N/A
5/12/2025	Q1 2025	AUPH Aurinia Pharmaceuticals	$0.08	$0.16	+$0.08	$0.16	$61.06 million	$62.47 million
5/8/2025	Q1 2025	GPCR Structure Therapeutics	-$0.24	-$0.27	-$0.03	-$0.27	N/A	N/A
5/1/2025	Q1 2025	ARDX Ardelyx	-$0.10	-$0.17	-$0.07	-$0.17	$79.40 million	$74.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARDX Ardelyx	N/A	N/A	N/A	N/A	N/A
AUPH Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AURA Aura Biosciences	N/A	N/A	N/A	N/A	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARDX Ardelyx	1.04	4.12	3.81
AUPH Aurinia Pharmaceuticals	0.16	5.93	5.26
AURA Aura Biosciences	N/A	11.06	11.06
GPCR Structure Therapeutics	N/A	23.29	23.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARDX Ardelyx	58.92%
AUPH Aurinia Pharmaceuticals	36.83%
AURA Aura Biosciences	96.75%
GPCR Structure Therapeutics	91.78%

Insider Ownership

Company	Insider Ownership
ARDX Ardelyx	4.80%
AUPH Aurinia Pharmaceuticals	12.20%
AURA Aura Biosciences	5.40%
GPCR Structure Therapeutics	9.43%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARDX Ardelyx	90	239.26 million	227.77 million	Optionable
AUPH Aurinia Pharmaceuticals	300	135.10 million	118.62 million	Optionable
AURA Aura Biosciences	50	50.27 million	47.55 million	Not Optionable
GPCR Structure Therapeutics	136	57.34 million	51.94 million	Optionable

AURA, ARDX, GPCR, and AUPH Headlines

Recent News About These Companies

Principal Financial Group Inc. Lowers Holdings in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR)

July 13, 2025 | marketbeat.com

Structure Therapeutics (NASDAQ:GPCR) Trading Down 7.3% - Here's Why

July 7, 2025 | marketbeat.com

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Receives Average Rating of "Buy" from Brokerages

July 3, 2025 | marketbeat.com

Structure Therapeutics (NASDAQ:GPCR) Shares Down 4% - Here's Why

June 26, 2025 | marketbeat.com

Jefferies Reiterates a Buy Rating on Structure Therapeutics (GPCR) With a $79 PT

June 24, 2025 | msn.com

Structure Therapeutics (NASDAQ:GPCR) Shares Up 4.7% - Time to Buy?

June 23, 2025 | marketbeat.com

Cantor Fitzgerald Reaffirms "Overweight" Rating for Structure Therapeutics (NASDAQ:GPCR)

June 23, 2025 | marketbeat.com

JMP Securities Reiterates "Market Outperform" Rating for Structure Therapeutics (NASDAQ:GPCR)

June 23, 2025 | marketbeat.com

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671

June 20, 2025 | globenewswire.com

Structure Therapeutics: Why Aleniglipron's Path To Market Remains Treacherous

June 10, 2025 | seekingalpha.com

Structure Therapeutics Reports First Quarter 2025 Financial Results and Recent Highlights

May 9, 2025 | finance.yahoo.com

Citigroup Initiates Coverage of Structure Therapeutics Inc. - Depositary Receipt () (GPCR) with Buy Recommendation

May 3, 2025 | msn.com

Structure draws new Buy at Citi on oral obesity drug pipeline

May 2, 2025 | msn.com

Viking among notable gainers as Pfizer raises deal prospects

April 29, 2025 | msn.com

Is Structure Therapeutics Inc. (NASDAQ:GPCR) the Most Promising Small-Cap Stock According to Analysts?

April 26, 2025 | msn.com

H.C. Wainwright maintains buy on Structure Therapeutics shares

April 24, 2025 | uk.investing.com

Researchers crack the code of cell movement

April 24, 2025 | sciencedaily.comS

Eli Lilly jumps as results from weight-loss pill study rival competitor’s

April 17, 2025 | markets.businessinsider.com

Why did Lilly data for oral GLP-1 boost Structure and Metsera?

April 17, 2025 | seekingalpha.com

SA Asks: What's the best weight-loss drug stock right now?

April 17, 2025 | msn.com

Why Structure Therapeutics Inc.’s (GPCR) Stock Is Up 29.14%

April 17, 2025 | aaii.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Chipotle: Too Spicy for Smart Money to Resist After Stock Split
By Jeffrey Neal Johnson | July 11, 2025
View Chipotle: Too Spicy for Smart Money to Resist After Stock Split
Buybacks Galore: Repurchases From the Oval Office to Olive Garden
By Leo Miller | June 30, 2025
View Buybacks Galore: Repurchases From the Oval Office to Olive Garden
3 Fast Food Stocks That Won’t Give You Indigestion Right Now
By Brian O'Connell | July 16, 2025
View 3 Fast Food Stocks That Won’t Give You Indigestion Right Now
Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback
By Thomas Hughes | June 23, 2025
View Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback
How Texas Roadhouse Is Winning in a Changing Consumer Market
By Dan Schmidt | July 14, 2025
View How Texas Roadhouse Is Winning in a Changing Consumer Market

AURA, ARDX, GPCR, and AUPH Company Descriptions

Ardelyx NASDAQ:ARDX

$4.42 +0.01 (+0.23%)

Closing price 07/21/2025 04:00 PM Eastern

Extended Trading

$4.43 +0.01 (+0.34%)

As of 06:46 AM Eastern

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Aurinia Pharmaceuticals NASDAQ:AUPH

$8.62 -0.01 (-0.12%)

Closing price 07/21/2025 04:00 PM Eastern

Extended Trading

$8.67 +0.05 (+0.58%)

As of 07/21/2025 07:51 PM Eastern

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Aura Biosciences NASDAQ:AURA

$6.77 +0.06 (+0.89%)

Closing price 07/21/2025 04:00 PM Eastern

Extended Trading

$6.88 +0.11 (+1.55%)

As of 07/21/2025 06:00 PM Eastern

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Structure Therapeutics NASDAQ:GPCR

$18.13 -1.12 (-5.82%)

Closing price 07/21/2025 04:00 PM Eastern

Extended Trading

$18.15 +0.02 (+0.09%)

As of 04:58 AM Eastern

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time